Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell TherapiesGlobeNewsWire • 09/07/21
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical BenefitGlobeNewsWire • 09/05/21
Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock OptionsZacks Investment Research • 08/16/21
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021GlobeNewsWire • 07/28/21
Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming CatalystsSeeking Alpha • 06/16/21
Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls24/7 Wall Street • 05/28/21
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer SettingsBenzinga • 05/20/21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 TrialGlobeNewsWire • 05/19/21
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study ShowsBenzinga • 05/11/21
First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal ModelGlobeNewsWire • 05/11/21
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCTGlobeNewsWire • 04/27/21
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021GlobeNewsWire • 04/22/21
Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business UpdateGlobeNewsWire • 02/25/21
Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors, Speculative InvestmentSeeking Alpha • 12/10/20
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor DayGlobeNewsWire • 11/20/20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOSGlobeNewsWire • 11/19/20